Bnp Paribas null (BN55B) News

Immatics Announces First Quarter 2024 Financial Results and Business Update

Company Provides Clinical Data Update from Ongoing Phase 1 Clinical Trial with ACTengine® IMA203 TCR-T...

Immatics Announces Full Year 2023 Financial Results and Corporate Update

Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 424B5 - Prospectus [Rule 424(b)(5)]

Immatics Announces Pricing of $175 Million Public Offering

Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Immatics Announces Proposed Public Offering

Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a...

DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing

DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing PR Newswire COLOGNE, Germany and ZURICH, Jan. 16...

DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing

DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing PR Newswire COLOGNE, Germany and ZURICH, Jan. 16...

Levicept Appoints Eliot Forster as CEO

Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for...

Immatics Announces Third Quarter 2023 Financial Results and Business Update

ACTengine® IMA203 GEN1 TCR-T targeting PRAME showed 50% (6/12) confirmed ORR in melanoma patients with median...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial

Company to host conference call and webcast today, November 8, at 8:30 am EST/2:30 pm CET IMA203 data with...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy

  RMAT designation granted by FDA CBER for IMA203 cell therapy in multiple PRAME-expressing tumors including...